ArticleDiscover oncology2025
Research trends and visualization analysis of autoimmune disease-related liver cancer from 2004 to 2024: a bibliometric study.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundDespite the rapid increase in scientific research output related to autoimmune disease-associated liver cancer (ADRLC) in recent years, there is currently a lack of a comprehensive and objective grasp of the cutting-edge progress and future research directions in this research field.
methodsA comprehensive bibliometric analysis of ADRLC literature was conducted using Biblioshiny, VOSviewer, Scimago Graphica, CiteSpace, and Microsoft Office Excel (Version 2022). Data were extracted from the Web of Science Core Collection (2004-2024).
resultsA total of 1,672 ADRLC papers published from 2004 to 2024 were included. The number of global publications increased steadily, peaking in 2023. The United States had the most publications and citations, followed closely by China and Japan. The WORLD JOURNAL OF GASTROENTEROLOGY published the most articles. High-frequency keywords included "hepatocellular carcinom", "cancer", and "disease" six major research clusters were identified, with "natural history" having the strongest burst impact from 2004 to 2024. Recent trends included "immunotherapy" and "cancer" (2021-2024). Cutting-edge research directions were "immunotherapy" and "immune checkpoint inhibitors".
conclusionThis study reveals the research directions and trends of ADRLC. The research on ADRLC is increasing globally, with significant contributions from China and the United States. Strengthening research on pathogenesis, early prevention, and individualized treatment of ADRLC is needed. Immunotherapy shows great potential in treating ADRLC and has become a current research hotspot.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.